Pulmonx (LUNG) Expected to Release Earnings on Tuesday

Key Points

• Pulmonx is expected to report Q3 2026 results after the market closes on October 27, with analysts forecasting a loss of $0.26 per share and revenue of $21.93 million.
• The company’s previous quarter exceeded expectations, reporting a $0.24 per-share loss versus the projected $0.28 loss and revenue of $22.76 million versus the $22.39 million consensus.
• Shares opened at $1.75, while analysts maintain a “Moderate Buy” consensus and an average price target of $7.67; however, Pulmonx remains unprofitable, with negative margins and projected full-year EPS of negative $1.05.

Pulmonx (NASDAQ:LUNG - Get Free Report) is anticipated to announce its Q3 2026 results after the market closes on Tuesday, October 27th. Analysts expect Pulmonx to post earnings of ($0.26) per share and revenue of $21.93 million for the quarter. Interested persons are encouraged to explore the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 4:30 PM ET.

Pulmonx (NASDAQ:LUNG - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.04. Pulmonx had a negative return on equity of 96.66% and a negative net margin of 55.03%. The business had revenue of $22.76 million for the quarter, compared to analysts' expectations of $22.39 million. On average, analysts expect Pulmonx to post ($1.05) EPS for the current fiscal year and ($0.94) EPS for the next fiscal year.

Pulmonx Stock Performance

Shares of LUNG opened at $1.75 on Tuesday. The business's fifty day simple moving average is $2.06 and its two-hundred day simple moving average is $1.65. The company has a current ratio of 4.32, a quick ratio of 3.52 and a debt-to-equity ratio of 0.95. Pulmonx has a 12 month low of $1.13 and a 12 month high of $2.89. The company has a market cap of $75.16 million, a price-to-earnings ratio of -1.51 and a beta of 0.33.

Insiders Place Their Bets

In other Pulmonx news, General Counsel David Lehman sold 14,334 shares of the business's stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $2.26, for a total transaction of $32,394.84. Following the completion of the sale, the general counsel directly owned 361,827 shares in the company, valued at $817,729.02. The trade was a 3.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Srikanth Radhakrishnan sold 14,245 shares of the company's stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $2.26, for a total transaction of $32,193.70. Following the sale, the insider directly owned 316,994 shares of the company's stock, valued at $716,406.44. The trade was a 4.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 78,340 shares of company stock valued at $177,048. Insiders own 7.50% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on LUNG shares. Wall Street Zen upgraded Pulmonx from a "sell" rating to a "hold" rating in a research note on Saturday, June 27th. Weiss Ratings raised Pulmonx from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, August 25th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Pulmonx presently has an average rating of "Moderate Buy" and an average target price of $7.67.

Pulmonx Company Profile

Pulmonx Corporation is a medical device company focused on developing and commercializing minimally invasive treatments for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its technologies are designed to improve lung function and quality of life by reducing the impact of damaged, overinflated portions of the lungs.

The company's primary product is the Zephyr Endobronchial Valve, a small, one-way valve placed in the airways during a bronchoscopic procedure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.